In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed to target mutated EGFR. However, there is little information regarding mutation specific potency of EGFR-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro, Naoki, Katsuhiko, Costa, Daniel B., Kobayashi, Susumu S., Betsuyaku, Tomoko, Soejima, Kenzo
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4770737/
https://ncbi.nlm.nih.gov/pubmed/26515464
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars